Categories for News

OPTIMA: Improving treatment for patients with prostate, breast and lung cancer through artificial intelligence

Professors Claude Chelala and Louise Jones from Barts Cancer Institute, Queen Mary University of London, are part of a €21.3 million public-private research programme that will seek to use artificial intelligence (AI) to improve care for patients with prostate, breast and lung cancer. The aim of the research project, named OPTIMA (Optimal Treatment for Patients with Solid Tumours in Europe Through Artificial intelligence), is to design, develop and...

Queen Mary researchers including Director of Barts Life Sciences Rakesh Uppal help develop nasal spray that prevents Covid-19

Queen Mary University of London professors Rakesh Uppal and Áine McKnight have been at the centre of a new clinical trial finding that pHOXWELL – a nasal spray developed by biotech company pHOXBIO – reduced SARS-CoV-2 infection by 63 per cent in the group given pHOXWELL compared to the group given the placebo. SARS-CoV-2 is the virus that causes Covid-19....

Barts Life Sciences is recruiting for a data warehouse manager

An exciting opportunity has arisen to work as part of our precision medicine team at Barts Life Sciences.  More information and how to apply can be found here: http://jobs.bartshealth.nhs.uk/job/UK/London/London/Barts_Health_NHS_Trust/Administrative_Clerical/Administrative_Clerical-v3441257?_ts=24451 Closing date: 12th September

AI technology at Barts Life Sciences spares at-risk diabetic patients from limb amputation

Thousands of diabetes patients could be spared a limb amputation thanks to ground-breaking AI technology that has helped Barts Life Sciences identify people at risk from complications. Clinicians at Barts Health NHS Trust, one of the largest trusts in the UK, say it would have taken a clinician over 100 years to review the volume of data analysed in a...

AI revolution at Barts Health NHS Trust could help thousands of diabetes patients avoid leg and foot amputations

Clinithink artificial intelligence software takes just weeks to sift through data that would take a human more than a century – enabling quicker treatment that could save limbs The Clinithink software analysed 14.2 million medical records and notes to identify patients with diabetic foot disease. A new AI technology being trialled at a major NHS hosptial trust could transform treatment...

Barts Life Sciences CEO Professor Sir Mark Caulfield to give keynote address at SEHTA MedTech conference October 2021

Barts Life Sciences and SEHTA are delighted to announce that Professor Sir Mark Caulfield, CEO of Barts Life Sciences will be the keynote speaker at the SEHTA 2021 International MedTech Expo & Conference. About the conference: Friday 8th October 2021, Hilton London Tower Bridge Hotel www.sehtamedtechexpo.co.uk The SME focused healthcare event driving collaborations between business, care, clinicians & academics Improving...

Remote but even more engaged: How to involve patients in your research in the age of digital-first

By Sophie Williams, Digital Pioneer Fellow Patient input is vital to medical research. Scientists need to hear about patient experiences to be sure that they are researching the most pressing questions. In a clinical trial the potential benefit of a new drug needs to be clearly explained to convince an individual to join the trial. But in data research the...

AI predicts diabetes risk by measuring fat around the heart

A team led by researchers from Queen Mary University of London has developed a new artificial intelligence (AI) tool that is able to automatically measure the amount of fat around the heart from MRI scan images. Using the new tool, the team was able to show that a larger amount of fat around the heart is associated with significantly greater...

New Covid-19 vaccine trial opens to recruitment at Barts Health

A clinical trial testing a new Oxford / AstraZeneca vaccine against Covid-19 has opened to recruitment at Barts Health NHS Trust. Volunteers are needed to take part in the study (a phase II/III clinical trial), which is led by the University of Oxford and AstraZeneca and supported by the National Institute of Health Research. The trial aims to test the...

Professor Sir Mark Caulfield appointed as CEO of Barts Life Sciences

Professor Sir Mark Caulfield has been announced as the new Chief Executive Officer of Barts Life Sciences. Barts Life Sciences, a research and innovation partnership between Barts Health NHS Trust and Queen Mary University of London, is driving the development of a world-leading life sciences campus at Whitechapel focusing on digital health, genomics and clinical innovation. The programme aims to develop...